5.59
0.04 (0.72%)
| 前收盘价格 | 5.55 |
| 收盘价格 | 5.39 |
| 成交量 | 101,373 |
| 平均成交量 (3个月) | 285,284 |
| 市值 | 200,903,488 |
| 价格/销量 (P/S) | 73.58 |
| 股市价格/股市净资产 (P/B) | 63.33 |
| 52周波幅 |
| 营业利益率 (TTM) | -2,585.09% |
| 稀释每股收益 (EPS TTM) | -1.98 |
| 季度收入增长率 (YOY) | -9.50% |
| 总债务/股东权益 (D/E MRQ) | 58.68% |
| 流动比率 (MRQ) | 0.960 |
| 营业现金流 (OCF TTM) | -69.19 M |
| 杠杆自由现金流 (LFCF TTM) | -40.90 M |
| 资产报酬率 (ROA TTM) | -195.55% |
| 股东权益报酬率 (ROE TTM) | -697.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
| Medical Instruments & Supplies (全球的) | 混合的 | 混合的 | |
| 股票 | Anteris Technologies Global Cor | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.0 |
| 平均 | -0.25 |
|
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Small Value |
| 内部持股比例 | 7.55% |
| 机构持股比例 | 22.01% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合